Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CC-96191 |
Synonyms | |
Therapy Description |
CC-96191 is a tri-specific antibody targeting CD33, NKG2D, and CD16a, which activates natural killer (NK) cells and potentially induces lysis of CD33-positive tumor cells (PMID: 38473239). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CC-96191 | CC96191|CC 96191|BMS-986357|BMS986357|BMS 986357 | CD33 Antibody 13 | CC-96191 is a tri-specific antibody targeting CD33, NKG2D, and CD16a, which activates natural killer (NK) cells and potentially induces lysis of CD33-positive tumor cells (PMID: 38473239). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04789655 | Phase I | CC-96191 | Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | FRA | CAN | 0 |